Partner Headlines - MDVN

  1. Chip Stocks, Biotechs Lead Another Nasdaq Rally

    IBD
  2. Major Upgrades And Downgrades In Friday's Market Action

    Benzinga
  3. Medivation Hits High After Q3 Earnings Beat

    IBD
  4. Medivation Hits High After Q3 Earnings Beat

    IBD
  5. Medivation and Astellas Announce Phase 3 Study of Enzalutamide ...

    GuruFocus
  6. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD
  7. Consider Medivation for Your Portfolio

    FoxBusiness
  8. Benzinga's Top Downgrades

    Benzinga
  9. Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

    Benzinga
  10. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  11. Fast Money Halftime Report Final Trade From September 12

    Benzinga
  12. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  13. Stifel Raises Medivation Inc Price Target

    Benzinga
  14. Stocks Hitting 52-Week Highs

    Benzinga
  15. A Few Reasons Why Investors Should Consider Dendreon for Their ...

    GuruFocus
  16. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD
  17. Benzinga's Volume Movers

    Benzinga
  18. Medivation Announces Change in Executive Management Team; Dawn ...

    Benzinga
  19. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  20. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  21. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  22. Benzinga's Top Upgrades

    Benzinga
  23. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  24. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  25. Morning Market Movers

    Benzinga
  26. Stocks To Watch For April 1, 2014

    Benzinga
  27. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  28. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  29. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  30. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  31. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  32. Benzinga's Top #PreMarket Losers

    Benzinga
  33. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  34. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  35. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  36. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  37. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  38. Stocks Hitting 52-Week Highs

    Benzinga
  39. Benzinga's Top #PreMarket Gainers

    Benzinga
  40. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  41. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  42. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  43. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  44. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  45. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  46. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  47. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  48. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  49. Benzinga's Top Initiations

    Benzinga
  50. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  51. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  52. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga
  53. Medivation Effects 2-for-1 Stock Split

    Benzinga
  54. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga
  55. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant ...

    Benzinga
  56. Medivation Reports 2-for-1 Forward Split of Common Stock

    Benzinga
  57. Andreas Halvorsen Buys 2 Million Shares of Medivation

    GuruFocus
  58. Medivation Inc. (MDVN) President and CEO David Hung sells 25, ...

    GuruFocus
  59. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  60. Stocks Hitting 52-Week Highs

    Benzinga
  61. Health Care Sector Wrap

    FoxBusiness
  62. Four Winning Trades Based on Analyst Calls

    Benzinga
  63. Medivation Bull Looks to Cash In on Continued Rally

    SchaeffersResearch
  64. Analyst Upgrades: MDVN, SCHN, and STI

    SchaeffersResearch
  65. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  66. Citigroup Reiterates Buy Rating, $129 PT for Medivation

    Benzinga
  67. Medivation and Astellas Announce Enzalutamide Data

    Benzinga
  68. Crazy Action in Medivation After Negative StreetSweeper Post

    Benzinga
  69. Global Fears and Small Caps: How Much of an Impact?

    Benzinga
  70. Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

    Benzinga
  71. GlaxoSmithKline, Vertex Point To Biotech Strength

    IBD
  72. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  73. Will Johnson & Johnson Cure Cancer?

    Benzinga
  74. Options Players Show a Preference for Medivation Puts

    SchaeffersResearch
  75. Notable Put Options Activity in Medivation

    Benzinga
  76. Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, ...

    GuruFocus
  77. Medivation's Stellar Technical Performance Entices Option Bulls

    SchaeffersResearch
  78. Benzinga's M&A Chatter for Wednesday February 1, 2012

    Benzinga
  79. Medivation Soars on Phase III Trial Data; Stock Up 21%

    Benzinga
  80. Jefferies Raises PT on Medivation to $95

    Benzinga
  81. Wedbush Raises PT on Medivation to $81

    Benzinga
  82. Medivation and Astellas Announce Positive Results From the Phase ...

    Benzinga
  83. Upgrades & Downgrades: AZO, MDVN, POT, TSLA, and UA

    SchaeffersResearch
  84. Gilead, Celgene Join Big Pharma On M&A Front

    IBD
  85. Alzheimer's drug test halted

    IBD
  86. Best Biotech Stocks of 2011

    Benzinga
  87. Options Players Get Bearish with Medivation Puts

    SchaeffersResearch
  88. Notable Put Options Activity in Medivation

    Benzinga
  89. Put Volume Heats Up as Medivation Surges to a New High

    SchaeffersResearch
Trading Center